Purpose: Cerebral perfusion is commonly assessed clinically with dynamic susceptibility contrast MRI using a bolus injection of gadolinium-based contrast agents, resulting in semi-quantitative values of cerebral blood volume (CBV). Steady-state imaging with ferumoxytol allows estimation of CBV with the potential for higher precision and accuracy. Prior CBV studies have focused on the signal disrupting T Ã 2 effects, but ferumoxytol also has high signalenhancing T 1 relaxivity. The purpose of this study was to investigate and compare CBV estimation using T 1 and T Ã 2 , with the goal of understanding the contrast mechanisms and quantitative differences. Methods: Changes in R 1 (1/T 1 ) and R Ã 2 (1/T Ã 2 ) were measured after the administration of ferumoxytol using high-resolution quantitative approaches. Images were acquired at 3.0T and R 1 was estimated from an ultrashort echo time variable flip angle approach, while R Ã 2 was estimated from a multiple gradient echo sequence. Twenty healthy volunteers were imaged at two doses. CBV was derived and compared from relaxometry in gray and white matter using different approaches. Results: R 1 measurements showed a linear dependence of blood R 1 with respect to dose in large vessels, in contrast to the nonlinear dose-dependence of blood R Ã 2 estimates. In the brain parenchyma, R Ã 2 showed linear dose-dependency whereas R 1 showed nonlinearity. CBV calculations based on R Ã 2 changes in tissue and ferumoxytol blood concentration estimates based on R 1 relaxivity showed the lowest variability in our cohort. Conclusions: CBV measurements were successfully derived using a combined approach of R 1 and R 
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INTRODUCTION
Intracranial vascular hemodynamics and vascular architecture are modified in a wide array of diseases, including tumors, stroke, and varying forms of dementia (1, 2) . Increasing evidence exists indicating pathologic alterations of the cerebral vasculature in Alzheimer's disease (AD) and dementia with Lewy bodies patients (3) (4) (5) (6) . In light of the mounting evidence, there is a necessity to assess the cerebrovascular network. In particular, non-invasive methods capable of quantitatively assessing diffuse cerebral disease are highly desirable.
MRI enables non-invasive measurements of hemodynamics and structure in the cerebrovascular network. Blood flow is routinely assessed with phase contrast (PC) MRI (7), and contrast and non-contrast angiographic MR techniques are widely available for the evaluation of vessel structure. Cerebral perfusion can be assessed using noncontrast arterial spin labeling (ASL) or dynamic imaging during administration of an exogenous contrast agent. Clinically, cerebral perfusion is commonly assessed using gadolinium-based contrast agents (GBCA) and dynamic susceptibility contrast (DSC)-MRI that exploits the T 2 /T shortening effect of the GBCA. DSC-MRI can provide estimates of cerebral blood volume (CBV) and flow (CBF) (8) . DSC-MRI is also capable of detecting changes in blood vessel density and vessel size (9) (10) (11) and holds potential to identify tumor angiogenesis using T 2 -weighted 2D and 3D acquisitions (12) .
Currently available GBCAs have short plasma half-lives. Therefore, the current clinical standard method to assess CBV is based on T Ã 2 -weighted imaging during bolus injection of GBCA. This approach requires high temporal resolution to capture the rapid arterial transit, which limits the achievable spatial resolution. Measures of CBV are derived from a joint analysis of dynamic signal from an arterial input (e.g., AIF) and the tissue of interest, and requires a conversion from signal to concentration. Such CBV measures are sensitive to the quality of arterial input measures and sensitive to errors in the concentration estimate, which arise from the diffusion of water between compartments (13, 14) , partial volume effects, and nonlinear signal relationships. Moreover, if the blood-brain barrier is compromised, contrast can leak into the interstitium, confounding quantitative estimates of CBV. Because of these challenges, most current applications of DSC-MRI do not attempt to quantify CBV using an AIF but instead assess relative differences in CBV between different brain regions. Relative CBV measurements are subject to variations because of differing injection protocols. Using a reference region to normalize the DSC signal may improve interscan reproducibility, however, this assumes that regions of pathology can be readily distinguished. In chronic neurodegenerative diseases such AD, characterized by the loss of neurons in the cerebral cortex, disease may be diffuse such that drawing reference regions of interest is not practical. Absolute CBV quantification may enable the identification of global and regional pathologic CBV with higher reproducibility. Concerns regarding the safety of GBCAs in patients with renal failure because of the possibility of nephrogenic systemic fibrosis (NSF) and more recently, gadolinium deposition in deep brain nuclei, are also important considerations (15) (16) (17) (18) (19) .
An attractive alternative for CBV assessment with MRI is the use of ferumoxytol, a dextran-coated ultra-small superparamagnetic iron oxide (USPIO) particle approved for the treatment of anemia in patients with chronic kidney disease (20) . Ferumoxytol exhibits strong T 1 and T Ã 2 shortening effects, has a long intravascular half-life (12-14 h), and is showing promise for off-label use as an MRI contrast agent (21, 22) . Compared to previously proposed intravascular GBCA (23, 24) , ferumoxytol has much stronger T Ã 2 shortening effects. Although the bolus injection of ferumoxytol is not currently recommended, steady-state imaging of ferumoxytol may be used to estimate cerebrovascular parameters, such as CBV (25) (26) (27) . Similar USPIOs have been successfully used in vessel size imaging studies that combine T 2 -and T Ã 2 -weighted acquisitions and in a DSC-MRI study for diagnosis of primary central nervous system inflammatory diseases (10, 28) . In 2015, the U.S. Food and Drug Administration (FDA) released a Safety Communication announcement strengthening warnings regarding the use and prescription of ferumoxytol (Feraheme) over concerns of potentially fatal allergic reactions. However, more recent studies have shown that serious adverse events are rare, and with proper precautions, ferumoxytol may be a valuable contrast agent (29) (30) (31) (32) (33) .
A potential approach for steady-state CBV estimation with ferumoxytol is to measure changes in the effective transverse relaxation rate (R Ã 2 ) pre-and post-contrast administration. This is done by assuming a linear relationship between tissue concentration of the contrast agent (CA) and R Ã 2 changes. However, CBV estimates from measurements of changes in R Ã 2 (DR Ã 2 ) are biased in tissues neighboring large vessels, bone, or air-tissue boundaries (34) . This complicates DR Ã 2 -based CBV estimates in the brain parenchyma, particularly in the gray matter, where there is higher vessel density, and regions such as the cerebellum, which is adjacent to the bony skull base and air-tissue interfaces of the mastoid cells. Although ferumoxytol studies of CBV to date have focused on the T Ã 2 effects, ferumoxytol also has high T 1 relaxivity. T Ã 2 and T 1 shortening effects (e.g., dynamic contrast enhanced [DCE] MRI) have substantially different mechanism to affect the extravascular signal. This presents an opportunity to probe different aspects of vascular remodeling, if accurate and co-registered T 1 and T Ã 2 mapping can be achieved. For example, T 1 -based techniques are sensitive to water exchange with the tissue whereas susceptibility-based techniques are not (35) .
The purpose of this study was to investigate the correlation between T 1 and T Ã 2 changes in brain tissue and blood, measured before and after the administration of ferumoxytol using quantitative R 1 and R Ã 2 relaxometry. R 1 was estimated from an ultrashort echo time variable flip angle approach (UTE-VFA), simultaneously mitigating bias from flow and T Ã 2 -decay effects, whereas R Ã 2 was estimated from a multiple gradient echo sequence. In a cohort of healthy human subjects, CBV was derived and compared from relaxometry in gray matter (GM) and white matter (WM) using three different steady state approaches: (1) using a derived linear relationship using only R Ã 2 in tissue, (2) a combinative approach using measurements of R Ã 2 in tissue and R 1 in blood, and (3) by fitting a two-compartment water exchange limited relaxation model using R 1 in tissue and blood.
METHODS

Subjects
Twenty-two healthy subjects (age range ¼ 20-61 y, mean ¼ 32 y, 12 females) were prospectively recruited from an Institutional Review Board approved database. This study was Health Insurance Portability and Accountability Act (HIPAA)-compliant and the local Institutional Review Board approved all study procedures and protocols following the policies and guidance established by the campus Human Research Protection Program (HRPP). Each participant provided signed informed consent before participation. The administration of ferumoxytol followed recently published guidelines on the safe use of ferumoxytol for research (22) .
MR Imaging Protocol
3D volumetric MRI images were acquired using UTE-VFA T 1 and multi-echo T Ã 2 mapping sequences on a 3.0T scanner (MR750, GE Healthcare, Waukesha, WI) with a 32-ch head coil (Nova Medical, Wilmington, MA). For all subjects, scanning was carried out before and after the administration of two doses of ferumoxytol. Ferumoxytol was diluted at least 5-fold up to 60 mL in normal saline, and injected as a slow infusion. Images were acquired at 3 time points: (1) pre-contrast, (2) after a first injection (1 mg Fe/kg), and (3) after a second injection (4 mg Fe/kg), for a total ferumoxytol dose of 5 mg Fe/kg. The timing between the two ferumoxytol injections ranged from 15 to 20 min for all subjects. UTE-VFA images were acquired using a 3D radial sampling trajectory with the following imaging parameters: echo time (TE)/pulse repetition time ¼ 0. (36, 37) . Actual flip angle (AFI) images were also acquired from which B 1 maps were generated (38) . 3D multi-echo gradient echo images using a Cartesian sampling trajectory were acquired with: pulse repetition time ¼ 32.5 ms, 8 equally spaced TEs acquired in a single pulse repetition time, ranging from 2.2 ms to 29.8 ms, flip angle ¼ 15 , 1 mm isotropic resolution, field of view ¼ 256 Â 180 Â 240 mm 3 and scan time ¼ 5:00 min.
Post Processing B 1 maps generated from AFI images were combined with the fitting of the UTE-VFA images to obtain R 1 (1/T 1 ) images. R
2 ) images were generated from complex fitting of the multi-echo images, fitting for the off-resonance, R Ã 2 , and signal density. Both R Ã 2 and R 1 fitting was carried out with a multi-resolution search of complex images coil-combined with the method proposed by Walsh et al. (39) . A total of 6 sets of images were generated per subject, R 1 and R Ã 2 maps for each of the 3 ferumoxytol concentrations (pre-contrast, 1 mg Fe/kg, 5 mg Fe/kg). Images were co-registered in MATLAB (The MathWorks, Natick, MA) using a rigid body registration using the source images. Subjective reader assessment for image quality was performed by two radiologists (one senior neuroradiologist with >30 y of experience and one radiologist with >10 y of experience). For each subject, partial volume masks (PVMs) of GM and WM were generated in FMRIB's Automated Segmentation Tool in the FSL software library package from the registered precontrast R 1 and R Ã 2 images (40) . A combined R 1 and R Ã 2 segmentation approach was used to avoid possible confounding errors in R 1 and R Ã 2 measurements in tissues because of the presence of nearby vessels. Additionally, to improve tissue segmentation, non-brain tissue was removed from the R 1 and R Ã 2 images before generating the PVMs using the Brain Extraction Tool in FSL (41) . PVMs were converted to binary masks in MATLAB by assigning a value of 1 to voxels with at least 95% GM or WM and 0 to the remaining voxels. The GM and WM masks were further eroded by a single voxel using ImageJ (National Institute of Health, Bethesda, MD). Finally, to measure local R 1 and R Ã 2 values, the GM and WM masks were combined with the R 1 and R Ã 2 images. To estimate the R 1 and R Ã 2 values of blood, a region of interest was manually drawn in the superior sagittal sinus (42) . Measurements in the sinus were averaged over 5 slices. Pixel-wise changes were analyzed in the registered images and cumulated into 2D histograms. These data were projected along the R 1 and R Ã 2 values at two different dose concentrations (1 mg Fe/kg and 5 mg Fe/kg).
CBV Estimation
CBV in tissue was estimated using steady-state approaches using R Ã 2 data alone, R Ã 2 data with blood concentration from R 1 data, and from R 1 data alone. From R Ã 2 data, CBV was estimated using the assumption of static dephasing using a model of randomly oriented cylinders previously described analytically and verified in Monte Carlo simulations (10, 43, 44) . In this approach, CBV is given by:
where CBV has units of fraction of blood in tissue, DR Ã 2 is the measured change in tissue relaxation rate, g is the proton gyromagnetic ratio equal to 2.675 Â 10 8 rad/s/T, B 0 is the main magnetic field, and Dx USPIO is the change of magnetic susceptibility of blood after injection of ferumoxytol, and is given by:
where M sat is the saturation magnetization of ferumoxytol, and is equal to 0.396 mT/mM of iron, and C b is the concentration of ferumoxytol in blood (mM ¼ mmol/L) (45) (46) (47) . Two approaches were used to estimate C b . The first approach uses the formula:
M Fe is the standard atomic weight of iron, m FE the injected mass of ferumoxytol, and TBV is the total blood volume computed using Nadler's formula (48) . The second approach used to estimate C b is given by:
where DR 1 blood , the measured change in blood relaxation rate, was used to estimate the concentration of ferumoxytol in blood by exploiting the linear relationship of R 1 in blood and ferumoxytol concentration. The R 1 relaxivity of ferumoxytol in blood (i.e., r 1 ) at 3.0T was determined in ex vivo experiments and was equal to 8.6725 s À1 mM À1 . The linear correlation between R 1blood and concentration of contrast agent in blood C b , was investigated in ex vivo experiments at 3.0T using ferumoxytol in whole human blood with hematocrit ¼ 42%. The manuscript on the report of that study is in preparation for publication elsewhere.
CBV was also estimated using R 1 in blood and tissue by fitting a two-compartment water exchange limited relaxation model (49) . This model gives a quantitative description of the effect of relative CBV and intra-/extravascular water exchange rates on the effective tissue longitudinal tissue relaxation rates. Using this model, it can be shown that the Bloch equation, including terms for the two-compartment water exchange, has the following solution for R 1 (49):
where R 1 is the measured tissue relaxation rate, R 1b and R 1e are the relaxation rates in blood and the extravascular space, respectively, PS is the water permeability surface area product between the intra-/extravascular space, CBV is the cerebral blood volume, and l, which is the ratio of the proton spin densities of tissue and blood, is assumed to be 0.9, similar to the previously reported value (49) . The PS product was derived with units of mL/s/g tissue and CBV with units of fraction of blood in tissue (represented as mL/100 g tissue), to follow the literature convention (49) , by assuming a tissue density of 1 g/mL. The CBV units for both R Ã 2 -and R 1 -based analysis are equivalent.
To determine the PS product, R 1e and CBV values, a three-parameter, nonlinear least squares fit was applied to Eq. [5] , using 3 data points (0, 1 mg Fe/kg, and 5 mg Fe/kg doses). A limitation of fitting R 1 to a two-compartment water exchange model is the uncertainty in the measured PS product. This tissue-dependent value will vary with individual subjects and is not easily measurable in a clinical setting (13, 14) . To investigate the uncertainty in the measured PS product, the parameter t b can be defined as the ratio of CBV and PS product. t b is the capillary water molecule lifetime and is given by:
Assuming a fixed value for t b , a two-parameter fit can be performed to estimate CBV and R 1e using Eq. [5] and the R 1 measurements at two different ferumoxytol concentrations (0 and 5 mg Fe/kg).
Statistical Analysis
Values of CBV estimates were compared between GM and WM for all subjects. The differences between GM and WM CBV estimates was assessed using ANOVA followed by Tukey-Kramer method for pairwise comparison for adjusted means. The R 1 and R Ã 2 measurements used to estimate CBV are represented by the median value from histograms containing signal values from voxels from tissue after segmentation of WM and GM. Statistical analysis was carried out in MATLAB. P < 0.05 was set as the threshold for statistical significance.
RESULTS
From 22 enrolled volunteers, 20 subjects completed the study protocol (age range ¼ 20-61 y, mean ¼ 32 y, 11 females). One subject's scan session was incomplete because of hard drive storage failure in the MRI system console. Data from another subject were not included because of incomplete acquisition of the data, resulting from the subject not responding to instructions from the technician, and the scan stopped to assess the subject's condition. The subject's vital signs were immediately checked and were normal. The subject was oriented and appeared to be in no distress but the scan was not completed to allow for continued observation. The subject was released after 1 h and was symptom-free.
Representative R Ã 2 , R 1 , DR Ã 2 , and DR 1 images from a single slice of the volume from one subject are shown in Figure 1 . R 1 and R Ã 2 images were acquired at a similar spatial resolution, however, R Ã 2 estimates are susceptible to signal loss from static gradients from large vessels, which is visually apparent. R 1 estimates are unaffected by this artifact. R Ã 2 -based imaging provides more sensitivity, however, vessels are depicted better in R 1 albeit a lower signal-to-noise ratio (9, 50, 51) . The R 1 images provide better contrast between GM, WM, and cerebral spinal fluid than R Ã 2 images, although R Ã 2 images were more sensitive to show voxels containing vessels, as observed in the images histogram. Overall, however, there is good subjective agreement between the 3D UTE-VFA T 1 and 3D R Ã 2 mapping techniques, especially at the higher doses. R 1 and R Ã 2 estimates in WM and GM are summarized in Figure 2 . The R 1 estimates (Fig. 2a) show a weaker correlation with dose-response at high concentrations of ferumoxytol, with a coefficient of determination R 2 ¼ 0.27 in WM and 0.71 in GM. R Ã 2 ( Fig. 2b) exhibits a stronger dose-response in tissue having a coefficient of determination R 2 ¼ 0.91 for both GM and WM. Figure 3 shows the R 1 (Fig. 3a) and R Ã 2 ( Fig. 3b ) measurements observed in a blood vessel (superior sagittal sinus) across all subjects. In large vessels, R (Figs. 4c and 4d ) tends to exhibit changes where the DR 1 does not change, suggesting the susceptibility effect of blood is nonlocal and therefore affects low CBV tissues and the vessel size is overestimated in R Ã 2 images. 2D histograms for specific tissue type (GM and WM) were also investigated (Supporting Fig. S1 ). For WM tissue, the 2D histogram shows initially a faster increase in DR Ã 2 than DR 1 . The dependence of R 1 estimates in blood with body mass index at three different concentrations of ferumoxytol was investigated. Although there were variations in R 1 of the blood among subjects, no correlations in R 1 blood versus body mass index were found, suggesting variation in R 1 beyond those because of body mass index (Supporting Fig. S2) .
Results of the CBV estimates are summarized in Figure  5 . When using DR TBV calculation to estimate concentration of CA in blood, the mean values of CBV were 3.1 6 0.5% in GM and 1.6 6 0.2% in WM. Instead, if C b is estimate from the R 1 in blood, the mean values of CBV are 3.7 6 0.5% in GM and 1.8 6 0.2% in WM. Finally, the CBV estimates from using R 1 in blood and tissue to fit the twocompartment water exchange limited relaxation model were the lowest with averages of 2.0 6 0.9 mL/100 g GM and 1.2 6 0.9 mL/100 g WM tissue. CBV estimates in GM were significantly larger than CBV estimates in WM for the three approaches. The relaxation rate in the extravascular space (R 1e ) was 0.53 6 0.03 s À1 in GM and 0.83 6 0.04 s À1 in WM. The median value of the water permeability surface area product between the intra-/ extravascular space PS was 0.259 6 0.079 mL/s/g GM and 0.194 6 0.118 mL/s/g WM tissue. Least squares curve fit to the water exchange limited relaxation model in GM and WM for all subjects (N ¼ 20) are shown in Supporting Figures S3 and S4 . To investigate the uncertainty in the PS product, the parameter t b was fixed while fitting the two-compartment water exchange model. Using CBV estimated from the DR Ã 2 approaches, t b was measured to be 0.233 6 0.012 s. R 1 -based CBV measures were then estimated using a fixed t b (0.233 s) and a two-parameter fit of the two-compartment water exchange limited relaxation model resulting in CBV values of 3.7 6 0.7 mL/ 100 g GM and 1.9 6 0.8 mL/100 g WM tissue.
DISCUSSION AND CONCLUSIONS
In this study, we investigated changes in cerebral R 1 and R Ã 2 relaxometry before and after the administration of two escalating doses of ferumoxytol in a cohort of 20 healthy volunteers. The main findings of this study are a linear dependence of blood R 1 with respect to dose in large vessels, in contrast to the nonlinear dose-dependence of blood R Ã 2 estimates. In the brain parenchyma, however, R Ã 2 showed linear dose dependency whereas R 1 showed nonlinearity and signal saturation at higher doses. Finally, CBV estimates using different approaches to calculate ferumoxytol concentration in blood showed consistent values with statistically significant higher CBV estimates in GM when compared to CBV estimates in WM, similar to values reported in other studies (45) . CBV calculations based on R Ã 2 changes in tissue and ferumoxytol blood concentration estimates based on R 1 relaxivity showed the lowest variability in our cohort.
The nonlinear response to concentration in tissue remains a challenge in measuring CBV from R 1 relaxometry alone. This does not arise from a limited dynamic range of the R 1 sequence, given the wide range of flip angles used and the application of an ultrashort echo time readout, but rather the intrinsic complexity and nonlinearity of the relationship between the apparent R 1 in tissue and ferumoxytol concentration. Because the relaxation effect of the agent only affects protons within a very close proximity of the USPIO, rapid water exchange is required to carry the relaxation effects of the contrast agent beyond the plasma compartment (52, 53) . The linear behavior of R 1 in blood as a function of dose implies that the intra-/extracellular water exchange rate with red blood cells is much faster than the intra-/extravascular exchange rate (14) . Similar R 1 behavior in tissue and blood using a different USPIO has been observed in pig experiments (54) . Although the two-compartment fit is expected to correct for these factors, the fitting is challenging because of the sensitivity to the water permeability surface area product between the intra-/extravascular space.
FIG. 4. Pixel-wise relationship between DR
The nonlinear dose-dependence of R (25) . The nonlinear behavior of R Ã 2 in blood can make estimation of contrast agent concentration in blood challenging, whereas the linear behavior in tissue makes R Ã 2 a better estimate of blood volume in tissue and was used in the steady-state approach CBV estimations.
The pixel correlation plots in Figure 4 show that further complexities exist in the comparison of R increases in areas where DR 1 does not exhibit changes (i.e., DR 1 ¼ 0). This is observed in tissues such as cerebral spinal fluid and around vessels, suggesting that the non-local effects of susceptibility changes (e.g., vessel blooming) may contribute to the DR CBV estimates in GM and WM (Fig. 5) agree well with previous studies that also estimated CBV by exploiting R Ã 2 linearity of ferumoxytol in tissue using a steady state approach (45) . The CBV values were higher in both GM and WM when blood R 1 were used to estimate ferumoxytol concentration in blood. The resulting CBV estimates using this method are closer to CBV estimates derived from PET (55) . If exclusively R 1 from blood and tissue are used to estimate CBV, then a two-compartment water exchange limited relaxation model can be fit. The CBV estimation from fitting a two-compartment water exchange limited relaxation model was similar in WM but lower in GM when compared to another study that used the same model but a multi-echo imaging technique at 7T and GBCA (56) . A possible reason for these differences might be because of the fact that the mentioned study used multiple data points per subject to perform the 3 parameter fitting whereas in this study only 3 points were available per subject. Furthermore, the referenced study used DCE-MRI with a GBCA. A limitation of fitting R 1 measurements to a two-compartment water exchange model, is the uncertainty in the measured PS product or water permeability surface area product between the intra-/extravascular space. As mentioned before, this value will depend on tissue and is not easily measured because of a high level of sensitivity to noise. This occurs because at low concentrations, the observed change in R 1 is relatively similar for an increase in CBV or an increase in PS. To investigate how the uncertainty in the PS product affects the variance in the blood volume results, the parameter t b was estimated. The resulting CBV estimates showed a significant decrease in the spread of the data for both GM and WM. This illustrates The CBV values were higher in both GM and WM when exploiting both: R Ã 2 linearity of ferumoxytol in tissue using a steady-state approach and blood R 1 to estimate ferumoxytol concentration in blood (from left to right 1 st box, blue). Similar but lower CBV estimates were found in GM and WM when using Nadler's equations to estimate ferumoxytol concentration in blood (2 nd box, black). The CBV estimation from fitting three parameters into a two-compartment water exchange limited relaxation model were lowest in magnitude and higher in data spread for both GM and WM (3 rd box-red). To investigate the spread of the data CBV was estimated from a two-parameter fit assuming a value of t b ¼ 0.233 6 0.012 s (4 th box, gray). Although the CBV estimates from the two-parameter fit are forced by the R Ã 2 CBV estimates, the reduction in the spread of the data is real, revealing the PS product uncertainties will increase the spread of the CBV estimates.
the large PS product uncertainty affects the spread in the CBV estimates from fitting a two-compartment water exchange limited relaxation model. This limitation makes the combination of R Ã 2 linearity in tissue to estimate CBV and the linearity of R 1 in blood to estimate CA concentration more reproducible in a clinical setting. However, even with the limited number of data points to fit the two-compartment water exchange relaxation model the derived values of water PS product and CBV were reproducible and describe the measured tissue R 1 . Additionally, the two-compartment water exchange model implicitly assumes that the tissue vascular fraction is small such that the tissue R 1 recovery curve is approximately mono-exponential at all values of R 1b .
The R 1 values measured using the UTE-VFA technique demonstrated a high degree of correlation with R Ã 2 estimates and was highly effective in large vessels. The ability to depict large vessel changes and the potential to probe permeability changes suggest that this technique may be of value when combined with susceptibility based measures. UTE-VFA is well suited to capture the linear dose-dependence of R 1 after ferumoxytol administration in blood because of short echo times. Furthermore, UTE-based T 1 approaches using USPIO to generate CBV estimates have been successfully implemented in rat models recently (57) .
The proposed work showed several possible techniques to quantify CBV from ferumoxytol with increasing complexity. As a straightforward approach, DR Ã 2 can be measured in tissue and the concentration of blood can be estimated from population averages (e.g., Nadler's equation). R Ã 2 mapping is readily available on all vendor scanners and has been widely used in other organs. R Ã 2 has the advantage of being approximately linear in tissue but the disadvantage of being unable to probe water exchange and sensitivity to variation in total blood volume. The use of R 1 is attractive because of the potential to accurately quantify the concentration of blood and investigate water exchange. However, R 1 mapping is significantly more complex than R Ã 2 mapping, most notably it is sensitive to B 1 variations. Recent progress in this area has suggested a vast array of techniques to correct and compensate for B 1 ranging from separate scan calibration techniques (58) , as used here, to MR fingerprinting approaches with B 1 incorporation (59). Our results suggest the most accurate quantification requires both techniques. This adds additional scan time to the imaging protocol and more work is required to reduce these imaging times to those that are more clinically manageable. As ferumoxytol currently requires a slowly infused bolus, protocols should be designed that allow imaging during this infusion.
There are a number of limitations in this study. First, the hematocrit levels of brain tissue were not incorporated in the CBV estimates calculations. We assume R 1 in blood and plasma are similar. Recently, new methods have been proposed to estimate hematocrit analytically (60) . Ideally, more data points should be used to fit the R 1 in a blood and tissue two-compartment water exchange limited relaxation model. This study was limited to 3 points per subject, which might explain the lower CBV estimates when compared to the steady state R Ã 2 models. One potential limitation of R 2 /R Ã 2 based techniques is that they have reduced sensitivity as the vessel size is reduced below 10 mm. This arises from a transition to the diffusional narrowing regime from our assumed static dephasing regime. R Ã 2 gradient echo-based techniques have a sensitivity plateau at vessel diameters of 10 mm and larger. Therefore, in this study, the blood volume fraction measured in the brain parenchyma using the R Ã 2 -based method does not include all the contribution from the capillary vessel network (3-5 mm). The major contribution measured were from small-to-large vessels and some capillaries. The actual impact of vessel size is difficult to gauge as the effect is small compared to the variability in reference standard measurements, such as those derived from PET. The use of spin-echobased (T 2 ) imaging would provide an opportunity to reduced sensitivity to larger vessel diameters (9, 50, 51) but exhibits a similar loss in sensitivity as the vessel diameter is reduced.
In summary, we investigated the correlation between relaxometry changes in R 1 and R Ã 2 measured after the administration of ferumoxytol using quantitative T 1 and T Ã 2 imaging approaches in healthy volunteers. R 1 was estimated from an ultrashort echo time variable flip angle approach (UTE-VFA), whereas R Ã 2 was estimated using a multi-echo approach. Finally, CBV measurements were successfully derived for GM and WM using a combined approach of R 1 and R Ã 2 relaxometry, exploiting the linearity and accuracy of dose-dependent R 1 values in blood vessels and the higher signal sensitivity of R Ã 2 values in tissue.
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